Login to Your Account

Biotie Shares Drop as Roche Passes on 5-HT6 Drug SYN120

By Cormac Sheridan
Staff Writer

Wednesday, June 27, 2012
Shares in Biotie Therapies Oyj dropped nearly 10 percent Tuesday on news that Roche Holding AG decided not to exercise an option on its selective serotonin (5-hydroxytryptamine) receptor subtype 6 (5-HT6) antagonist SYN-120.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription